Apple Inc. (AAPL)’s iPhone 6 Production Delay is Unlikely to Happen

A report recently came out that pointed that Apple Inc. (NASDAQ:AAPL)‘s suppliers are having a hard time in getting enough screens ready for the launch of the rumored iPhone 6. The rumored iPhone 6 is supposed to come in two different models, one with a 4.7-inch screen and the other with a 5.5-inch screen. Re/code’s Co-executive editor, Kara Swisher, discussed the reports concerning delays in Apple Inc. (NASDAQ:AAPL)’s rumored iPhone 6 with the ‘Squawk Alley’ team on CNBC, recently.

AAPL Apple Store

“They are trying to make everything very thin, the phone is going to be very very thin. These are big phones compared to the sort of the way they are copying the Samsung phones, but they want it to be thinner and more beautiful. So, they are perfectionist at Apple Inc. (NASDAQ:AAPL). Again, these stories happen every time when Apple Inc. (NASDAQ:AAPL) has a product that there is delays, there is issues. They are going to be rolling out the phone and hopefully they will have enough depending on the demand, but I think there is going to be a lot of demand for these phones,” Swisher said.

In the course of the discussion, it was also revealed that there is no clarity over which of the rumored model will have a delay, though their are speculations that it’s going to be the 5.5-inch model instead of the 4.7-inch model. The one thing that is nearly sure  is that Apple Inc. (NASDAQ:AAPL) is going to launch one of these models by the end of this year.

“We don’t even know for sure, whether they plan to roll out two sizes at the same time. So, the call to delay, I don’t know, I mean I think the point is there has been, especially in developed markets, among higher end phones, a move toward larger sizes. If they come out with a 4.7, that’s a wide open field for them, where they are highly likely to steal share from Samsung and so potentially either way this is a good job,” Jon Fortt added.

Disclosure: None

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!